Geriatrik popülasyondaki meme kanserli hastaların klinik ve patolojik özellikleri

Year 2024, Volume: 49 Issue: 4, 958 - 964, 30.12.2024

Ömer Acar , Mustafa Şahbazlar

https://doi.org/10.17826/cumj.1529238

Abstract

Amaç: Meme kanseri teşhisi konulan hastaların önemli bir kısmı 65 yaşın üzerindedir. Yaşlı hastalar genellikle eşlik eden hastalıklar nedeniyle prospektif klinik çalışmalardan hariç tutulur. Klinisyenlerin yaşlı hastalar için farklı tedavi yönetimi seçenekleri vardır. Yetersiz tedavi veya aşırı tedavi tedavi sonuçlarını ve prognozu olumsuz etkileyebilir. Tedavi kararlarına rehberlik edecek çok az veri vardır. Kanser merkezimizde takip edilen yaşlı meme kanseri hastalarının klinik ve patolojik özelliklerini sunuyoruz.
Gereç ve Yöntem: Cerrahi olarak tedavi edilen meme kanseri hastalarının dosyalarının retrospektif bir incelemesi yapıldı. Genel sağkalım ve progresyonsuz sağkalım üzerindeki prognostik etki değerlendirildi.
Bulgular: Çalışma toplam 101 hastayı kapsıyordu. Ortanca yaş 67'ydi (65-81). Hastaların yaklaşık yarısı TNM evre 2 olarak sınıflandırıldı. Çoğunluğu modifiye radikal mastektomi geçirmişti. %15.8'i neoadjuvan kemoterapi aldı. %84.2'sinde invaziv duktal karsinom histolojik alt tipi vardı. Patolojik N3 lenf nodları olan ve neoadjuvan kemoterapi alan hastalarda ve HER2 pozitif hastalarda progresyonsuz sağkalım daha düşüktü. N3 patolojik lenf nodları olan hastalarda 5 yıllık sağkalım oranı %61,7, N2 patolojik lenf nodları olan hastalarda %91 ve N1 veya N0 patolojik lenf nodları olan hastalarda %100 idi.
Sonuç: Patolojik evre sağkalımla ilişkiliydi. Patolojik N3 lenf nodlarının varlığı daha düşük progresyonsuz sağkalım ve daha düşük genel sağkalımla sonuçlandı. Yaştan bağımsız olarak, iyi performans gösteren, güçsüz olmayan ve komorbiditesi olmayan hastalar güncel tedaviyi almaya teşvik edilmelidir.

Keywords

Geriatrik meme kanseri, genel sağ kalım, kırılganlık

Ethical Statement

This study was approved by the ethics committee of Manisa Celal Bayar University (29/05/2024 and No. 2439).

Supporting Institution

Authors declared no financial support

Thanks

Thank you to the staff at the archives

Clinical and pathological features of breast cancer patients in the geriatric population

Abstract

Purpose: A significant portion of patients diagnosed with breast cancer are over the age of 65. Elderly patients are often excluded from prospective clinical trials due to comorbidities. Clinicians have different treatment management options for elderly patients. Under-treatment or over-treatment may negatively affect treatment outcomes and prognosis. There are few data to guide treatment decisions. We present the clinical and pathological features of elderly breast cancer patients followed in our cancer center.
Materials and Methods: A retrospective review of files about surgically treated patients with breast cancer was conducted. The prognostic impact on overall survival and progression-free survival was assessed.
Results: The study encompassed a total of 101 patients. The median age was 67 (65-81) years. Approximately half of the patients were classified as TNM stage 2. The majority of them had undergone modified radical mastectomy. 15.8% received neoadjuvant chemotherapy. 84.2% had invasive ductal carcinoma histological subtype. progression-free survival was lower in patients receiving neoadjuvant chemotherapy with pathological N3 lymph nodes and in HER2-positive patients. The 5-year survival rate was 61.7% in patients with N3 pathological lymph nodes, 91% in those with N2 pathological lymph nodes, and 100% in patients with N1 or N0 pathological lymph nodes.
Conclusion: The pathological stage was associated with survival. The presence of pathological N3 lymph nodes resulted in lower progression-free survival and lower overall survival. Regardless of age, patients with good performance, who are not frail, and who have no comorbidities should be encouraged to receive current therapy.

Keywords

geriatric breast cancer, overall survival, fragility

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 countries. CA Cancer J Clin. 2021;71:209-49.
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7-33.
• Varghese F, Wong J. Breast cancer in the elderly. Surg Clin North Am. 2018;98:819-33.
• Bertolo A, Rosso C, Voutsadakis IA. Breast cancer in patients 80 years-old and older. Eur J Breast Health. 2020;16:208-12.
• Lodi M, Scheer L, Reix N, Heitz D, Carin AJ, Thiébaut N et al. Breast cancer in elderly women and altered clinico-pathological characteristics: a systematic review. Breast Cancer Res Treat. 2017;166:657-68.
• Frebault J, Bergom C, Cortina CS, Shukla ME, Zhang Y, Huang CC et al. Invasive breast cancer treatment patterns in women age 80 and over: A report from the national cancer database. Clin Breast Cancer. 2022;22:49-59.
• Frebault J, Bergom C, Kong AL. Surgery in the older patient with breast cancer. Curr Oncol Rep. 2019;21:69.
• Choi H, Noh H, Kim KM, Cho IJ, Lim S, Han A. Increasing mortality in korean patients with breast cancer: high mortality rate in elderly breast cancer population due to suboptimal treatment and other diseases. Cancer Control. 2021;28:10732748211037914.
• Biganzoli L, Battisti NML, Wildiers H, McCartney A, Colloca G, Kunkler IH et al. Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the european society of breast cancer specialists (EUSOMA) and the international society of geriatric oncology (SIOG). Lancet Oncol. 2021;22:e327-e340.
• T M A, Joseph P R, K R R, Soman S, Mathew M, Chacko S et al. Survival outcome and predictors of survival in elderly breast cancer patients following curative treatment. South Asian J Cancer. 2023;12:314-18.
• Kędzierawski P, Mężyk R. Breast cancer in women aged 75 years and older - tumour characteristics and treatment options. Prz Menopauzalny. 2021;20:14-20.
• Morgan JL, George J, Holmes G, Martin C, Reed MWR, Ward S et al. Breast cancer surgery in older women: outcomes of the bridging age gap in breast cancer study. Br J Surg. 2020;107:1468-79.
• Grossi S, Le J, Armani A. Omitting axillary staging in selected patients: rationale of choosing wisely in breast cancer treatment. Surgery. 2023;174:413-15.
• Whelan TJ, Smith S, Parpia S, Fyles AW, Bane A, Liu FF et al. Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer. N Engl J Med. 2023;389:612-19.
• Kinj R, Chand ME, Gal J, Gautier M, Lam Cham Kee D, Hannoun-Lévi JM. Five-year oncological outcome after a single fraction of accelerated partial breast irradiation in the elderly. Radiat Oncol. 2019;14:234.
• Tamirisa N, Lin H, Shen Y, Shaitelman SF, Sri Karuturi M, Giordano SH et al. Association of chemotherapy with survival in elderly patients with multiple comorbidities and estrogen receptor-positive, node-positive breast cancer. JAMA Oncol. 2020;6:1548-54.
• Ma SJ, Oladeru OT, Singh AK. Outcome of adjuvant chemotherapy in elderly patients with early-stage, hormone receptor-positive, HER-2-negative breast cancer. Breast J. 2020;26:2026-30.
• Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol. 2019;30:1178.
• Nardin S, Ruelle T, Giannubilo I, Del Mastro L. Adjuvant treatment in hormone receptor-positive early breast cancer: new approaches of endocrine therapy. Tumori. 2024;110:162-67.
• Qian X, Li Z, Ruan G, Tu C, Ding W. Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials. Breast Cancer Res Treat. 2020;179:275-85.
• Barchiesi G, Mazzotta M, Krasniqi E, Pizzuti L, Marinelli D, Capomolla E et al. Neoadjuvant endocrine therapy in breast cancer: current knowledge and future perspectives. Int J Mol Sci. 2020;21:3528.